Related Experiment Videos
[Amiodarone pulmonary toxicity]
L Mazzei1, B Sposato, A Propati
1I Unità Operativa di Broncopneumologia e Riabilitazione Respiratoria, Azienda Ospedaliera San Camillo-Forlanini, Roma.
Abstract:
The Authors discuss a case of amiodarone pulmonary toxicity, with simultaneous alveolar and interstitial infiltrates, in a female patient 75 years old, who took the drug for 6 months at a low dosage (200 mg/daily for 5 days a week). It is outlined that the diagnosis can be achieved only by exclusion of other aetiologies, since clinical and diagnostic features are not pathognomonic for such disease. The withdrawal of the drug and the administration of the steroid therapy determined a fast improvement of the clinical and radiological appearance.
Insights
A 75-year-old female developed amiodarone pulmonary toxicity despite low-dose, intermittent use. Diagnosis requires excluding other causes, and treatment involves drug withdrawal and steroids for rapid improvement.
Area of Science:
- Pulmonology
- Cardiology
- Pharmacology
Background:
- Amiodarone is a widely used antiarrhythmic drug.
- Pulmonary toxicity is a known but infrequent adverse effect of amiodarone.
- Diagnosis of amiodarone-induced lung injury can be challenging.
Observation:
- A 75-year-old female patient presented with respiratory symptoms after 6 months of low-dose amiodarone therapy (200 mg/daily, 5 days/week).
- Radiological imaging revealed simultaneous alveolar and interstitial infiltrates.
- Clinical and diagnostic features were not specific, necessitating exclusion of other potential causes.
Findings:
- The patient's presentation was consistent with amiodarone pulmonary toxicity.
- Diagnosis was established by excluding other potential etiologies for the observed pulmonary infiltrates.
- Discontinuation of amiodarone and initiation of corticosteroid therapy led to significant clinical and radiological improvement.
Implications:
- This case highlights that amiodarone pulmonary toxicity can occur even with low-dose, intermittent therapy.
- Early recognition and prompt management, including drug withdrawal and steroid administration, are crucial for favorable outcomes.
- Physicians should maintain a high index of suspicion for amiodarone-induced lung injury in patients on this medication, especially when pulmonary symptoms arise.